Detection of BRCA1, and BRCA2 Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World Setting

Background: Poly (ADP-ribose) polymerase (PARP) inhibitors are approved for patients with metastatic castration-resistant prostate cancer harboring deleterious or suspected deleterious BRCA1 and/or 2 mutations. Identifying patients with prostate cancer harboring these mutations may be challenging. C...

Descripción completa

Detalles Bibliográficos
Autores principales: McFarland, Taylor Ryan, Mathew Thomas, Vinay, Nussenzveig, Roberto, Gebrael, Georges, Sayegh, Nicolas, Tripathi, Nishita, Sahu, Kamal Kant, Goel, Divyam, Maughan, Benjamin L., Sirohi, Deepika, Agarwal, Neeraj, Swami, Umang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776086/
https://www.ncbi.nlm.nih.gov/pubmed/36551924
http://dx.doi.org/10.3390/biomedicines10123170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776086/
https://www.ncbi.nlm.nih.gov/pubmed/36551924
http://dx.doi.org/10.3390/biomedicines10123170

Ejemplares similares